Business Wire

Motorola Expands Indigenous Languages Support With Addition of Ladin

6.6.2024 16:00:00 EEST | Business Wire | Press release

Share

Motorola and the Lenovo Foundation are committed to inclusion and smarter technology for all, and today we reaffirm this dedication with the expansion of our Indigenous Languages Support Initiative. As part of our ongoing efforts to raise awareness and empower Indigenous communities, Motorola is proud to announce the addition of Ladin, a minority language spoken in Italy’s Dolomites region (South of Tyrol), to the list of over 90 languages supported in our smartphones.

United Nations Educational, Scientific and Cultural Organization (UNESCO) estimates that one Indigenous language disappears every two weeks, resulting in the potential loss of around 3,000 unique languages by the end of the century. That’s why over the past three years, Motorola has been at the forefront of this mission, championing the revitalization of endangered languages across the globe.

With a focus on Europe for our latest phase of the Indigenous Languages Support Initiative, Motorola conducted extensive research to identify minority and endangered languages needing support. Among the languages considered, Ladin became a significant candidate, being one of the 12 officially recognized minority languages in Italy and one of three without a kinstate, or entity that is close to the region where their kin-groups reside. With only 30,000 speakers, UNESCO classifies Ladin as an endangered language.

"We've learned over the past few years that it is imperative that we work closely with the community of speakers and scholars that are passionate and committed to saving and promoting the language,” said Janine Oliveira, Executive Director of Software Globalization, Motorola. “This rang true for the Ladin community and made the decision to digitize the language in our devices easy."

Motorola worked alongside the Lenovo Foundation, and several translators and reviewers from the Ladin Institute, Micurá de Rü, led by Professor Paul Videsott, Professor for Romance Philology at the Free University of Bozen-Bolzano (UNIBZ). “This will definitely help Ladin and other minority languages to be more visible,” said Professor Videsott. “Smartphones are like the pencil of the 21st century, and having minority languages, including Ladin, in the motorola edge 50 series, has the same importance of having a language in a book.”

At Motorola, we know indigenous populations are interacting with mobile technology and are one of many diverse groups that make up our valued consumer base. It’s why we started the project, as we aim to preserve human heritage and the unique histories of Indigenous cultures while empowering future generations. But we also believe we have a responsibility to inspire others to do the same. Through June 2024, Motorola has open-sourced over 1 million translated indigenous words, allowing other companies to promote these languages through their interfaces, furthering revitalization efforts worldwide. Today, we’re also excited to share the latest version of our Hello Indigenous whitepaper written in partnership with Lenovo Foundation and UNESCO, serving as a blueprint for others to follow in their footsteps.

Ladin is the latest of several endangered languages that Motorola has added to its smartphone interface, including Kuvi and Kangri (spoken in regions of India), Cherokee (spoken in the United States), Kaingang (spoken in Brazil) and Nheengatu (spoken in the Amazon). Motorola remains committed to our mission of inclusion and cultural preservation, leveraging technology to bridge linguistic divides and foster a more diverse and interconnected world. To access the full data sets for each of our digitized endangered Indigenous languages, please visit: https://www.motorola.com/us/about/endangered-indigenous-languages-data-set.

Legal Disclaimers

Certain features, functionality and product specifications may be network dependent and subject to additional terms, conditions, and charges. All are subject to change without notice. MOTOROLA, the Stylized M Logo, MOTO and the MOTO family of marks are trademarks of Motorola Trademark Holdings, LLC. ©2024 Motorola Mobility LLC. All rights reserved.

About Motorola & Lenovo

Lenovo is a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub. Motorola Mobility LLC was acquired by Lenovo Group Holdings in 2014. Motorola Mobility is a wholly owned subsidiary of Lenovo, and is responsible for designing and manufacturing all Moto and Motorola branded mobile handsets and solutions. To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub and Motorola Global Blog.

About Lenovo Foundation

Lenovo Foundation is the charitable and philanthropic arm of Lenovo, a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cassandra Marrero: marreroc@motorola.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye